title: Renal cell cancer treated with a single-edged sword.
abstract: Preclinical and early clinical data suggest that antiangiogenic treatments may lead to more aggressive tumors. In this issue of Cell Reports, Blagoev et al. (2013) show that sunitinib, a multikinase inhibitor with antiangiogenic effects, does not worsen the survival of patients with metastatic kidney cancer.
authors: Department of Medicine, Herbert Irving Comprehensive Cancer Center, Columbia University, 177 Fort Washington Avenue, MHB 6N-435, New York, NY 10032, USA.
authors: Emerson
authors: E
authors: Lim
authors: Edward P
authors: EP
authors: Gelmann
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy*; D006801:Humans; D007211:Indoles / Q000627:therapeutic use*; D007680:Kidney Neoplasms / Q000188:drug therapy*; D011758:Pyrroles / Q000627:therapeutic use*; D000077210:Sunitinib
chemical_list: D000970:Antineoplastic Agents; D007211:Indoles; D011758:Pyrroles; D000077210:Sunitinib